These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24711006)

  • 1. Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target.
    Pimplikar SW
    J Clin Immunol; 2014 Jul; 34 Suppl 1():S64-9. PubMed ID: 24711006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease.
    Webers A; Heneka MT; Gleeson PA
    Immunol Cell Biol; 2020 Jan; 98(1):28-41. PubMed ID: 31654430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting microglia for the treatment of Alzheimer's Disease.
    Wes PD; Sayed FA; Bard F; Gan L
    Glia; 2016 Oct; 64(10):1710-32. PubMed ID: 27100611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status and future directions of clinical trials in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.
    Blasko I; Grubeck-Loebenstein B
    Drugs Aging; 2003; 20(2):101-13. PubMed ID: 12534311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel Therapeutic Strategies for Alzheimer's Disease].
    Tomita T
    Brain Nerve; 2024 Sep; 76(9):1053-1058. PubMed ID: 39251225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization.
    Zotova E; Bharambe V; Cheaveau M; Morgan W; Holmes C; Harris S; Neal JW; Love S; Nicoll JA; Boche D
    Brain; 2013 Sep; 136(Pt 9):2677-96. PubMed ID: 23943781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
    Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
    Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
    Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
    J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau immunotherapy for Alzheimer's disease.
    Pedersen JT; Sigurdsson EM
    Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances and considerations in AD tau-targeted immunotherapy.
    Bittar A; Bhatt N; Kayed R
    Neurobiol Dis; 2020 Feb; 134():104707. PubMed ID: 31841678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.
    Vander Zanden CM; Chi EY
    J Pharm Sci; 2020 Jan; 109(1):68-73. PubMed ID: 31647950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.
    Counts SE; Lahiri DK
    Curr Alzheimer Res; 2014; 11(7):623-5. PubMed ID: 25156573
    [No Abstract]   [Full Text] [Related]  

  • 20. Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.
    Shadfar S; Hwang CJ; Lim MS; Choi DY; Hong JT
    Arch Pharm Res; 2015 Dec; 38(12):2106-19. PubMed ID: 26289122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.